McLellan, K., Das, R. E., Ekong, T. A. and Sesardic, D. (1996). Therapeutic botulinum toxin type A toxin: factors affecting potency. Toxicon, 34, 975–85.CrossRefGoogle ScholarPubMed

Aoki, K. R. (2001). A comparison of the safety margins of botulinum toxin serotypes. Journal of Neurology, 248(Suppl. 1), 3–10.CrossRefGoogle Scholar

Jankovic, J. and Orman, J. (1987). Botulinum A toxin for cranial-cervical dystonia: a double-blind placebo-controlled study. Neurology, 37, 616–23.CrossRefGoogle ScholarPubMed

Walker, F. O., Scott, G. E. and Butterworth, J. (1993). Sustained focal effects of low dose intramuscular succinylcholine. Muscle & Nerve, 16, 181–7.CrossRefGoogle ScholarPubMed

Ahmed, F., Magar, R., Marchetti, A. and Ferguson, I. (2003). European Journal of Neurology, 10(Suppl. 1), 162.

WeMove – Website. http://www.wemove.org

Odergren, T., Hjaltason, H., Kaakkola, S., Solders, G., Hanko, J., Fehling, C., Marttila, R. J., Lundh, H., Gedin, S., Westergren, I., Richardson, A., Dott, C. and Cohen, H. (1998). A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 64(1), 6–12.CrossRefGoogle ScholarPubMed

Turner-Stokes, L. and Ward, A. B. (2002). The management of adults with spasticity using botulinum toxin. Clinical Medicine, 2(2), 128–30.CrossRefGoogle ScholarPubMed

Gracies, J.-M., Weisz, D. J., Yang, B. Y., Flanagan, S. and Simpson, D. (2002). Effects of Botulinum Toxin Type A Dilution and Endplate Targeting Technique in Upper Limb Spasticity. Presented to American Neurological Association Meeting.

Sanders, I., Mu, L., Amirali, A.et al. (1998). Motor endplate mapping of the human biceps brachii muscle. Abstract. Ann. Neurol., 44, 501.Google Scholar

Shaari, C. M. and Sanders, I. (1993). Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve, 16, 964–9.CrossRefGoogle ScholarPubMed

Bigalke, H., Wohlfarth, K., Irmer, A. and Dengler, R. (2001). Botulinum A toxin: Dysport improvement of biological availability. Exp Neurol., 168(1), 162–70.CrossRefGoogle ScholarPubMed

Childers, M. K., Kornegay, J. N., Aoki, R., Otaviani, L., Bogan, D. J. and Petroski, G. (1998). Evaluating motor end-plate-targeted injections of botulinum toxin type A in a canine model. Muscle Nerve, 21(5), 653–5.3.0.CO;2-W>CrossRefGoogle Scholar

Koko, C. and Ward, A. B. (1997). Management of spasticity. British Journal of Hospital Medicine, 58(8), 400–5.Google Scholar

Berweck, S., Feldkamp, A., Francke, A., Nehles, J., Schwerin, A. and Heinen, F. (2002). Sonography-guided injection of botulinum toxin A in children with cerebral palsy. Neuropediatrics, 33(4), 221–3.CrossRefGoogle ScholarPubMed

Richardson, D. (2002). Physical therapy in spasticity. European Journal of Neurology, 9(Suppl. 1), 17–22.CrossRefGoogle ScholarPubMed

Carruthers, J. and Carruthers, A. (1998). The adjunctive usage of botulinum toxin. Dermatologic Surgery, 24(11), 1244–7.CrossRefGoogle ScholarPubMed

Jitpimolmard, S., Tiamkao, S. and Laopaiboon, M. (1998). Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. Journal of Neurology, Neurosurgery and Psychiatry, 64(6), 751–7.CrossRefGoogle ScholarPubMed

Dodel, R. C., Kirchner, A., Koehne-Volland, R., Kunig, G., Ceballos-Baumann, A., Naumann, M., Brashear, A., Richter, H. P., Szucs, T. D. and Oertel, W. H. (1997). Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics, 12(6), 695–706.CrossRefGoogle ScholarPubMed

Brashear, A., Zafonte, R., Corocran, M., Galvez-Jimenez, N., Gracies, J.-M., Gordon, M. F., Mcafee, A., Ruffing, K., Thompson, B., Williams, M., Lee, C.-H. and Turkel, C. (2002). Inter- and intra-rater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper limb post-stroke spasticity. Archives of Physical Medicine & Rehabilitation, 83(10), 1349–54.CrossRefGoogle Scholar

Sampaio, C., Ferreira, J. J., Simoes, F., Rosas, M. J., Magalhaes, M., Correia, A. P., Bastos-Lima, A., Martins, R. and Castro-Caldas, A. (1997). DYSBORT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A – Dysport and Botox – assuming a ratio of 4: 1. Movement Disorders, 12(6), 1013–18.CrossRefGoogle Scholar

Aoki, K. R. and Guyer, B. (2001). Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. European Journal of Neurology, 8(Suppl. 5), 21–9.CrossRefGoogle ScholarPubMed

Aoki, K. R. (2001). A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon, 39, 1815–20.CrossRefGoogle Scholar

Aoki, K. R. (2002). Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon, 40, 81–6.Google Scholar

Nussgens, Z. and Roggenkamper, P. (1997). Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Archive for Clinical and Experimental Ophthalmology, 235(4), 197–9.Google ScholarPubMed

Ranoux, D., Gury, C., Fondarai, J., Mas, J. L. and Zuber, M. (2002). Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 72(4), 459–62.Google ScholarPubMed

Erbguth, F.Claus, D., Engelhardt, A. and Dressler, D. (1993). Systemic effect of local botulinum toxin injections unmasks subclinical Lambert–Eaton myasthenic syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 56(11), 1235–6.CrossRefGoogle ScholarPubMed

Bachmeyer, C., Benz, R., Barth, H., Aktories, K., Gilbert, M. and Popoff, M.R. (2001). Interaction of Clostridium botulinum C2 toxin with lipid bilayer membranes and Vero cells: inhibition of channel function by chloroquine and related compounds in vitro and intoxification in vivo. FASEB Journal, 15(9), 1658–60.CrossRef

Davis, L. E., Johnson, J. K., Bicknell, J. M., Levy, H. and McEvoy, K. M. (1992). Human type A botulism and treatment with 3,4-aminopyridine. Electromyography and Clinical Neurophysiology, 32, 379–83.Google Scholar

Mezaki, T., Kaji, R., Kohara, N. and Kimura, J. (1996). Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection. Neurology, 46(3), 845–6.Google Scholar

Glanzman, R. L., Gelb, D. J., Drury, I., Bromberg, M. B. and Truong, D. D. (1990). Brachial plexopathy after botulinum toxin injections. Neurology, 40(7), 1143.CrossRefGoogle ScholarPubMed

Klein, A. W. (2002). Complications and adverse reactions with the use of botulinum toxin. Disease-A-Month, 48(5), 336–56.CrossRefGoogle ScholarPubMed

Wang, Y. C., Burr, D. H., Korthals, G. J. and Sugiyama, H. (1984). Acute toxicity of aminoglycoside antibiotics as an aid in detecting botulism. Appl. Environ. Microbiology, 48, 951–5.Google ScholarPubMed

Turner Stokes, L. and Ward, A. B. (2001). The Management of Adults with Spasticity – Guidelines for the Use of Botulinum Toxin Type A. Byfleet: Hourds.Google Scholar

Graham, H. K., Aoki, K. R., Autti-Rämo, I., Boyd, R. N., Delgado, M. R., Gaebler-Spira, D. J., Gormley, M. E., Guyer, B. M., Heinen, F., Holton, A. F., Matthews, M., Molenaers, G., Motta, F., García-Ruiz, P. J. and Wissel, J. (2000). Recommendations for the use of botulinum type A in the management of cerebral palsy. Gait and Posture, 11, 67–9.CrossRefGoogle ScholarPubMed

Berardelli, A., Abbruzzese, G., Bertolasi, L., Cantarella, G., Carella, F., Curra, A., Grandis, D., DeFazio, G., Galardi, G., Girlanda, P., Livrea, P., Modugno, N., Priori, A., Ruoppolo, G., Vacca, L. and Manfredi, M. (1997). Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology. Italian Journal of Neurological Sciences, 18(5), 261–9.CrossRefGoogle Scholar

Lowe, N. J., Sandeep, C., Halford, J., Jones, H., Payne, S. and Poyner, T. (2003). Guidelines for the primary care treatment and referral of focal hyperhidrosis. Guidelines, 381–91.Google Scholar

Jost, W. H., Kohl, A., Brinkmann, S. and Comes, G. (2005). Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J. Neural. Transm., 112, 905–13.CrossRefGoogle Scholar

Roggenkamper, P., Jost, W. H., Biharia, K., Comes, G. and Grafe, S. (2006). Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J. Neural. Transm. 113, 303–12.CrossRefGoogle ScholarPubMed

Benecke, R., Jost, W. H., Kanovsky, P., Ruzicka, E., Comes, G. and Grafe, S. (2005). A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology, 64, 1949–51.CrossRefGoogle ScholarPubMed